* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Sunday, July 20, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Canes owner Tom Dundon’s real estate firm eyes entertainment complex near RDU – The Business Journals

    Canes Owner Tom Dundon’s Real Estate Firm Unveils Plans for Thrilling New Entertainment Complex Near RDU

    Inspired Entertainment, Inc.’s (NASDAQ:INSE) Price Is Right But Growth Is Lacking After Shares Rocket 29% – simplywall.st

    Inspired Entertainment Soars 29% but Growth Momentum Falls Short

    Kroger shares summer entertainment tips – Supermarket Perimeter

    Ultimate Summer Entertainment Tips to Make Your Season Unforgettable

    Theater at Santa Fe’s San Isidro Plaza will be converted into IMAX, family entertainment venue – Santa Fe New Mexican

    Santa Fe’s San Isidro Plaza Theater Transforms into Exciting IMAX Family Entertainment Venue

    B&B Theatres will open massive entertainment complex in Texas – The Business Journals

    B&B Theatres will open massive entertainment complex in Texas – The Business Journals

    Rough times for broadcast networks illustrate changing media landscape – New Haven Register

    Broadcast Networks Confront Turbulent Times in a Rapidly Changing Media Landscape

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Bull of the Day: Credo Technology Group (CRDO) – Yahoo Finance

    Bull of the Day: Why Credo Technology Group (CRDO) Is Poised for a Breakout

    BlackSky Technology Inc. Stock Analysis and Forecast – Explosive wealth accumulation – Jammu Links News

    BlackSky Technology Inc.: Unlocking Explosive Wealth Potential Through Expert Stock Analysis and Forecast

    Polypurine Hairpin Technology is Safe, Effective at Inhibiting PCSK9 to Regulate Cholesterol – Pharmacy Times

    Polypurine Hairpin Technology: A Safe and Powerful Breakthrough for Controlling Cholesterol by Targeting PCSK9

    A major AI training data set contains millions of examples of personal data – MIT Technology Review

    A major AI training data set contains millions of examples of personal data – MIT Technology Review

    Simpson College to purchase medical simulation technology with grant funds – Iowa Capital Dispatch

    Simpson College to purchase medical simulation technology with grant funds – Iowa Capital Dispatch

    SailGP Technologies officially launches new center of excellence in technology & innovation – Sail-World.com

    SailGP Technologies officially launches new center of excellence in technology & innovation – Sail-World.com

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Canes owner Tom Dundon’s real estate firm eyes entertainment complex near RDU – The Business Journals

    Canes Owner Tom Dundon’s Real Estate Firm Unveils Plans for Thrilling New Entertainment Complex Near RDU

    Inspired Entertainment, Inc.’s (NASDAQ:INSE) Price Is Right But Growth Is Lacking After Shares Rocket 29% – simplywall.st

    Inspired Entertainment Soars 29% but Growth Momentum Falls Short

    Kroger shares summer entertainment tips – Supermarket Perimeter

    Ultimate Summer Entertainment Tips to Make Your Season Unforgettable

    Theater at Santa Fe’s San Isidro Plaza will be converted into IMAX, family entertainment venue – Santa Fe New Mexican

    Santa Fe’s San Isidro Plaza Theater Transforms into Exciting IMAX Family Entertainment Venue

    B&B Theatres will open massive entertainment complex in Texas – The Business Journals

    B&B Theatres will open massive entertainment complex in Texas – The Business Journals

    Rough times for broadcast networks illustrate changing media landscape – New Haven Register

    Broadcast Networks Confront Turbulent Times in a Rapidly Changing Media Landscape

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Bull of the Day: Credo Technology Group (CRDO) – Yahoo Finance

    Bull of the Day: Why Credo Technology Group (CRDO) Is Poised for a Breakout

    BlackSky Technology Inc. Stock Analysis and Forecast – Explosive wealth accumulation – Jammu Links News

    BlackSky Technology Inc.: Unlocking Explosive Wealth Potential Through Expert Stock Analysis and Forecast

    Polypurine Hairpin Technology is Safe, Effective at Inhibiting PCSK9 to Regulate Cholesterol – Pharmacy Times

    Polypurine Hairpin Technology: A Safe and Powerful Breakthrough for Controlling Cholesterol by Targeting PCSK9

    A major AI training data set contains millions of examples of personal data – MIT Technology Review

    A major AI training data set contains millions of examples of personal data – MIT Technology Review

    Simpson College to purchase medical simulation technology with grant funds – Iowa Capital Dispatch

    Simpson College to purchase medical simulation technology with grant funds – Iowa Capital Dispatch

    SailGP Technologies officially launches new center of excellence in technology & innovation – Sail-World.com

    SailGP Technologies officially launches new center of excellence in technology & innovation – Sail-World.com

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer

December 7, 2023
in Health
Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer
Share on FacebookShare on Twitter

SAN ANTONIO — Adding tucatinib (Tukysa) to trastuzumab emtansine (T-DM1; Kadcyla) reduced the risk of disease progression or death by 24% in previously treated HER2-positive breast cancer patients with locally advanced unresectable or metastatic disease, a multinational phase III study found.

Median progression-free survival (PFS) reached 9.5 months with the anti-HER2 combination, as compared with 7.4 months with T-DM1 plus placebo (HR 0.76, 95% CI 0.61-0.95, P=0.0163), Sara Hurvitz, MD, of the Fred Hutchinson Cancer Center in Seattle, reported here at the San Antonio Breast Cancer Symposium.

Interim results on overall survival (OS) were currently “unreliable,” said Hurvitz, but appeared mixed. With 53% of events recorded for the final analysis, median OS was not reached in the combination arm versus 38 months in the placebo arm (HR 1.23, 95% CI 0.87-1.74).

While PFS among the large subset of patients with brain metastases was not formally tested, there was a strong trend favoring the tucatinib arm: median 7.8 months versus 5.7 months in the placebo arm (HR 0.64, 95% CI 0.46-0.89).

“This is the second randomized study which included patients with brain metastases to demonstrate that a tucatinib-containing regimen delays disease progression in HER2-positive advanced disease,” said Hurvitz during a press briefing.

Press briefing moderator Kate Lathrop, MD, of the Mays Cancer Center at UT Health San Antonio, observed that unlike in the current trial, patients in clinical practice do not routinely receive central nervous system imaging unless they have symptoms, meaning those with asymptomatic brain metastases who might benefit from earlier tucatinib are unlikely to be identified.

Hurvitz agreed and called it a “pressing need” to re-examine guidelines on how and when brain imaging is performed.

While current guidelines indicate that patients should only undergo brain imaging if they are symptomatic, “we are getting to a point now that we do have drugs that do have activity intracranially and may help us delay the need for whole brain radiation or even surgery,” Hurvitz said.

“We have no randomized studies looking at the optimal timing of brain imaging. Nor do we have studies that compare [starting with] systemic therapies like tucatinib to staring with local-regional therapy, and then adding in tucatinib,” she added. “These are studies that are going to be important for us in defining these guidelines.”

Explaining the rationale behind the current HER2CLIMB-02 study, Hurvitz pointed out that the incidence of brain metastases in patients with locally advanced unresectable or metastatic HER2-positive breast cancer remains high.

The previous HER2CLIMB trial — which led to tucatinib’s approval — showed that adding the HER2 tyrosine kinase inhibitor to a regimen containing trastuzumab and capecitabine significantly improved PFS and OS in heavily pretreated patients with metastatic HER2-positive disease, including those with brain metastases.

T-DM1 is a HER2-directed antibody-drug conjugate approved to treat advanced or metastatic HER2-positive breast cancer in patients previously treated with trastuzumab and a taxane. Hurvitz noted that preclinical data and a phase Ib/II study evaluating the combination of tucatinib and T-DM1 demonstrated encouraging antitumor activity as well as a manageable safety profile.

Study discussant Valentina Guarneri, MD, PhD, of the University of Padova in Italy, noted that patients with brain metastases have long been excluded from clinical trials.

“Since optimal therapy for these patients should not be an afterthought, clinical trials taking the risk of including these patients must be valued,” she said, and added that the data from this study “further supports studies in the early disease setting aiming at preventing the development of brain metastases.”

HER2CLIMB-02 included 463 HER2-positive breast cancer patients with locally advanced unresectable or metastatic disease who progressed after trastuzumab and a taxane in any setting. The trial allowed patients to enroll if they had previously treated stable, progressing, or untreated brain metastases not requiring immediate local therapy. The primary endpoint was PFS, with OS a secondary endpoint.

Participants were in their mid-50s, nearly all were women, and 43% were enrolled in North America. Roughly 44% had presence or history of brain metastases at baseline (half of which were active metastases), and 60% had hormone-receptor positive cancers. Just under half of the patients (46%) had initially been diagnosed with stage IV disease.

The median number of prior lines of systemic therapy in the metastatic setting was one (range 0-8), and Hurvitz noted that the vast majority of patients were previously treated with pertuzumab (Perjeta) and that prior use of trastuzumab deruxtecan (T-DXd; Enhertu) was an exclusion factor for the trial. At progression, nearly half of the patients in each study arm went on to receive T-DXd.

Regarding safety, the most common treatment-emergent adverse events (TEAEs) included nausea, diarrhea, and fatigue. Common grade ≥3 TEAEs were alanine and aspartate aminotransferase elevations (both 16.5% in the tucatinib arm and 2.6% in the placebo arm). Discontinuations due to TEAEs were more frequent in the tucatinib arm.

author['full_name']

Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

Disclosures

The study was sponsored by Seagen, in collaboration with Merck Sharp & Dohme.

Hurvitz reported relationships with Seattle Genetics/Seagen, Ambrx, Arvinas, AstraZeneca, Atossa, Bayer, Celcuity, Curio/Vaniam, CytomX, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, Greenwich Life Sciences, GSK, Immunomedics, Eli Lilly, Loxo, Macrogenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Designs, Pieris, Puma, Quantum Leap, Radius, Sanofi, and Zymeworks.

Guarneri reported relationships with AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, GSK, Novartis, Pfizer, Olema Oncology, Pierre Fabre, and Zentiva.

Lathrop reported receiving an educational grant from Pfizer.

Primary Source

San Antonio Breast Cancer Symposium

Source Reference: Hurvitz S, et al “HER2-CLIMB-02: randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer” SABCS 2023; Abstract GS01-10.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/sabcs/107713

Tags: healthRegimenTucatinib
Previous Post

Experts, Senators Wrestle Over Thorny Drug Shortage Challenge

Next Post

JAK Inhibitor Preserves Beta-Cell Function in Early Type 1 Diabetes

Bull of the Day: Credo Technology Group (CRDO) – Yahoo Finance

Bull of the Day: Why Credo Technology Group (CRDO) Is Poised for a Breakout

July 20, 2025
Euro 2025: Germany Beats France on PKs to Reach Semifinals Despite Red Card – FOX Sports

Euro 2025 Showdown: Germany Edges Past France on Penalties to Reach Semifinals Despite Red Card

July 20, 2025
July 16 – Property owners fined $204,000 for damaging Deschutes River shoreline – Department of Ecology – State of Washington (.gov)

Property Owners Hit with $204,000 Fine for Destroying Deschutes River Shoreline

July 20, 2025
Scientists Found the Staggering Natural Switch That Could Bring Back Your Eyesight – Popular Mechanics

Scientists Discover Incredible Natural Switch That Could Restore Your Vision

July 20, 2025
UW scientists use AI to crack ‘undruggable’ proteins, opening door to new treatments – GeekWire

UW scientists use AI to crack ‘undruggable’ proteins, opening door to new treatments – GeekWire

July 20, 2025
EXCLUSIVE: Von Dutch Expands Reach With New Lifestyle Venture, Thanks Charli XCX for ‘Reigniting Gen Z’s Interest’ – WWD

Von Dutch Sparks Gen Z Excitement with Bold New Lifestyle Venture Inspired by Charli XCX

July 20, 2025
Pacquiao held to draw by Barrios in world title return – Yahoo Sports

Pacquiao’s Epic Comeback Fight Ends in a Heart-Stopping Draw Against Barrios

July 20, 2025
The kitchen sink has been thrown at the economy. Here’s why it’s not causing a recession. – MarketWatch

The kitchen sink has been thrown at the economy. Here’s why it’s not causing a recession. – MarketWatch

July 20, 2025
Canes owner Tom Dundon’s real estate firm eyes entertainment complex near RDU – The Business Journals

Canes Owner Tom Dundon’s Real Estate Firm Unveils Plans for Thrilling New Entertainment Complex Near RDU

July 20, 2025
Your health insurance premiums could soon go up 15 percent — or more – vox.com

Brace Yourself: Health Insurance Premiums Could Soar by 15%

July 20, 2025

Categories

Archives

July 2025
MTWTFSS
 123456
78910111213
14151617181920
21222324252627
28293031 
« Jun    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (730)
  • Economy (753)
  • Entertainment (21,638)
  • General (16,003)
  • Health (9,791)
  • Lifestyle (761)
  • News (22,149)
  • People (755)
  • Politics (762)
  • Science (15,970)
  • Sports (21,251)
  • Technology (15,736)
  • World (736)

Recent News

Bull of the Day: Credo Technology Group (CRDO) – Yahoo Finance

Bull of the Day: Why Credo Technology Group (CRDO) Is Poised for a Breakout

July 20, 2025
Euro 2025: Germany Beats France on PKs to Reach Semifinals Despite Red Card – FOX Sports

Euro 2025 Showdown: Germany Edges Past France on Penalties to Reach Semifinals Despite Red Card

July 20, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version